Related Experiment Video
Updated: May 27, 2026

08:30
Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction
Published on: August 21, 2016
Genome-wide methylation profiling in archival formalin-fixed paraffin-embedded tissue samples
J Keith Killian1, Robert L Walker, Sven Bilke
1Cancer Genetics Branch, National Institutes of Health/National Cancer Institute, Bethesda, MD, USA.
Methods in Molecular Biology (Clifton, N.J.)
|November 15, 2011
Summary
We optimized DNA methylation analysis for archival pathology samples, enabling biomarker discovery. This method enhances the clinical utility of DNA methylation signatures in routine specimens.
Area of Science:
- Epigenetics
- Molecular Pathology
- Biomarker Discovery
Background:
- Genome-scale DNA methylation measurement technologies are advancing.
- DNA methylation holds potential as a clinical biomarker.
- Archival formalin-fixed paraffin-embedded (FFPE) specimens are valuable resources.
Purpose of the Study:
- To adapt a commercial bisulfite epigenotyping assay for genome-wide methylation profiling.
- To demonstrate the feasibility of using archival FFPE pathology specimens for this analysis.
- To guide biomarker discovery experiments for identifying DNA methylation signatures.
Main Methods:
- Adaptation of a commercial bisulfite epigenotyping assay.
- Application to archival formalin-fixed paraffin-embedded (FFPE) pathology specimens.
- Step-by-step protocol for genome-wide methylation profiling and biomarker discovery.
Main Results:
- Successful genome-wide DNA methylation profiling in archival FFPE specimens.
- Demonstration of a methodology for identifying phenotype-correlated DNA methylation signatures.
- Establishment of a workflow for biomarker discovery using routine pathology samples.
Conclusions:
- The adapted assay is suitable for genome-wide DNA methylation analysis in archival FFPE tissues.
- This approach increases the clinical utility of DNA methylation as a biomarker.
- The methodology facilitates the discovery of novel methylation-based biomarkers from readily available pathology specimens.

